Nearly one in five women with early-stage breast cancer received guideline-discordant treatment, usually with regards to chemotherapy use.
The dose-rounding of certain monoclonal antibodies plus or minus 10% produced significant cost and waste savings.
A panel presented at ASHP highlighted the anticipated advancements expected in payment models in 2018, alongside the use of analytics and claims data for optimal health care payment strategies.
Guideline-based management approaches can improve quality of care and outcomes for patients with heart failure and arrhythmic complications.
Real-World Data Shows Similar Rate of Hypoglycemia Events With Insulin Glargine Injection, Insulin Degludec
Adults with type 2 diabetes who switched from basal insulin therapy to insulin glargine injection experienced similar numbers of hypoglycemia events and decreases in average HbA1c as those who switched to insulin degludec.
In patients with HER2-positive metastatic gastric cancer, subcutaneous administration of a common therapy results in significant time savings for health care providers as well as reduced costs.
A single-agent therapy conferred a favorable safety profile and exhibited evidence of durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma.
A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Elderly patients with acute myeloid leukemia faced high health care costs in their first year following diagnosis.
Patients with sickle cell disease who are insured through Medicaid used hematology care services at a far lower rate than commercially insured patients.